Pioglitazone is an agonist of the peroxisome proliferator-activated receptor γ (PPARγ) and has been widely used in the treatment of type 2 diabetes mellitus (T2DM) for several decades. This evidence concerns the gene PPARG and type 2 diabetes mellitus.